The market is capitulating on Perrigo due to headline EPS losses and a collapsing share price, but is ignoring the company's strong cash flow, asset base, and the unsustainably high dividend yield. The disconnect between accounting losses and underlying cash generation implies a forced selling dynamic, not a true business collapse.
Bear
$7
-35%
35%
Base
$14
+29%
45%
Bull
$22
+103%
20%
Catalysts
Announcement of asset sales or strategic alternatives
Dividend maintained or cut with clear turnaround plan
Stabilization of cash flow and improved guidance
Risk Factors
Dividend cut without credible restructuring
Further cash flow deterioration from OTC competition
Regulatory or legal liabilities impacting cash
Key Debates
PRGO's Net Margin turns positive by H1 2025, re-rating P/S to 0.6x.
PRGO's D/E ratio falls below 1.0 by Q3 2025, de-risking the balance sheet.
PRGO rallies over 50% by Q1 2025, triggering a short squeeze to $15+.
Recent Daily Analysis
— Today’s 5.5% surge is the market beginning to price in a specific catalyst: a strategic action to simplify Perrigo's convoluted corporate structure. The stock's absurdly low 4.8x forward P/E is not a reflection of its underlying asset quality but a steep 'complexity discount' applied by investors who cannot model its disparate consumer and pharma segments together. We hypothesize this value will be unlocked not by incremental earnings beats, but by a decisive corporate action. If management signals a 'portfolio review' or intent to divest a major division on its next earnings call, it will force a re-rating toward pure-play consumer health peers that trade at multiples of 15-20x P/E.